ALX Oncology Holdings Inc. filings document a clinical-stage biotechnology issuer focused on cancer therapeutics and its Nasdaq-listed common stock. Recent 8-K reports furnish quarterly and annual financial results, corporate updates, clinical data releases for evorpacept and ALX2004, preliminary cash and investment information, and capital-structure disclosures tied to common stock and pre-funded warrant financing.
Proxy and governance filings describe board matters, executive compensation, equity awards, and shareholder voting items. Other material-event reports cover officer appointments, employment and compensatory arrangements, and amendments to the 2025 Inducement Equity Incentive Plan under Nasdaq inducement award rules.
ALX Oncology Holdings Inc. agreed to issue venBio Global Strategic Fund, L.P. a pre-funded warrant to purchase up to 253,826 common shares in exchange for Fund I surrendering 253,826 shares for no consideration. The exchange and warrant issuance were expected on or about October 15, 2026, subject to satisfaction or waiver of the Exchange Agreement’s conditions. The warrant has a $0.001-per-share exercise price and may be exercised on or after issuance.
Fund I reports beneficial ownership of 4,307,034 shares (3.3%), including 129,260 shares issuable under the warrant subject to the ownership limitation; Fund II reports 8,453,038 shares (6.5%). Corey Goodman, sole director of GP Ltd. I and GP Ltd. II, may be deemed to beneficially own 12,927,442 shares (9.99%). Goodman resigned from ALX Oncology’s board effective June 29, 2026; Robert Adelman ceased serving as a director of the general partners and is no longer a reporting person. David Pezeshki is identified as the notice contact and as attorney-in-fact for Goodman.
ALX Oncology Holdings Inc. entered into separate privately negotiated exchange agreements on October 14, 2026, under which certain stockholders agreed to surrender an aggregate of 13,353,384 common shares, and the company agreed to issue pre-funded warrants to purchase an aggregate of 13,353,384 common shares. The exchange is to settle on or about October 15, 2026. Participating holders included funds affiliated with Blackstone Annex Master Fund L.P. for 12,885,891 shares, RA Capital Healthcare Fund, L.P. for 213,667 shares and venBio Global Strategic Fund, L.P. for 253,826 shares.
Each warrant has a $0.001 per-share exercise price and is exercisable on or after issuance until exercised in full, subject to its ownership limits. Holders may pay in immediately available funds or use a cashless exercise. A holder and its attribution affiliates may not exercise if that would result in beneficial ownership above the warrant’s specified 4.99% or 9.99% limit, measured against common shares or combined voting power. A holder may change the limit to another percentage up to 19.99%; any increase becomes effective on the 61st day after notice to the company.
ALX ONCOLOGY HOLDINGS INC (ALXO) director and chief executive officer Jason Lettmann reported a sale of 2,230 shares of Common Stock on August 17, 2026 at $1.93 per share. The shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Following this transaction, he directly owned 294,379 shares, which includes 3,000 shares acquired under the issuer's employee stock purchase plan on June 30, 2026.
ALX Oncology Holdings Inc. (ALXO) reported that officer Shelly Wong, SVP, Finance and CAO, sold 573 shares of Common Stock on 2026-08-17 at $1.93 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the vesting of restricted stock units. After this transaction, Wong directly holds 87,828 shares of ALXO common stock.
ALX Oncology Holdings Inc. received an amended Schedule 13G from TCG Crossover investment entities and Chen Yu updating their reported ownership of the company’s common stock. TCG Crossover Fund II, L.P. and its general partner TCG Crossover GP II, LLC each report beneficial ownership of 2,827,739 shares, or 2.1% of the outstanding common stock, with shared voting and dispositive power over these shares. TCG Crossover Fund III, L.P. and TCG Crossover GP III, LLC each report beneficial ownership of 2,827,748 shares, or 2.1% of the class, also on a shared-power basis.
Chen Yu, as sole managing member of both TCG Crossover GP II and TCG Crossover GP III, may be deemed to beneficially own an aggregate 5,655,487 shares, representing 4.2% of ALX Oncology’s common stock, based on 134,562,917 shares outstanding as of May 1, 2026. The reporting persons state that they disclaim beneficial ownership of the securities except to the extent of their pecuniary interest and also note that they are reporting ownership of 5 percent or less of the class.
ALX Oncology Holdings Inc. reported unaudited results for the quarter ended June 30, 2026, as it continues to develop its evorpacept and ALX2004 oncology programs. The company has not realized product revenues from its planned principal operations and remains focused on clinical trials in HER2‑positive and EGFR‑expressing cancers.
For the three months ended June 30, 2026, net loss was $17,971 thousand, or $(0.13) per share, compared with $25,949 thousand, or $(0.49) per share, a year earlier. Total operating expenses were $18,033 thousand, driven mainly by research and development of $13,138 thousand and general and administrative expense of $5,133 thousand, and included a $238 thousand lease termination gain versus a $3,175 thousand impairment charge in 2025.
Liquidity increased significantly. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026, compared with $48.3 million at December 31, 2025, reflecting a February 2026 registered equity offering that generated approximately $140.4 million in net proceeds and a new $10.0 million HSBC term loan that refinanced prior debt. Net cash used in operating activities was $34,705 thousand for the first half of 2026, and management states existing capital resources are expected to fund projected operating requirements for at least the next twelve months after the financial statements are issued.
ALX Oncology Holdings Inc. reported second quarter 2026 results, with GAAP net loss of $18.0 million for the three months ended June 30, 2026, compared with $25.9 million a year earlier. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026, which the company expects will fund planned operations through the first half of 2028.
Research and development expenses were $13.1 million, down from $18.0 million, reflecting lower legacy trial costs while continuing to invest in the Phase 2 ASPEN-09-Breast evorpacept trial and the Phase 1 ALX2004 study. Non-GAAP net loss was $14.3 million, compared with $20.6 million in the prior-year quarter.
The company highlighted progress in its oncology pipeline, including biomarker-driven evorpacept data presented at ESMO Breast Cancer 2026 and ongoing enrollment in ASPEN-09-Breast with topline data from 80 patients expected in mid-2027. Enrollment continues in the Phase 1 ALX2004 antibody-drug conjugate trial in EGFR-expressing solid tumors, with initial safety data expected in the second half of 2026. ALX Oncology refinanced $10 million of existing debt and entered into a secured multi-tranche term loan facility of up to $50 million, including the ability to draw an additional $20 million through June 2028, and appointed Scott Garland as Chairman and Michael Listgarten as General Counsel.
BlackRock, Inc. filed a Schedule 13G reporting passive ownership of common stock of ALX Oncology Holdings Inc. BlackRock and its reporting business units beneficially own 7,327,850 ALXO shares, representing 5.4% of the outstanding common stock as of the filing.
BlackRock reports sole voting power over 7,231,560 shares and sole dispositive power over 7,327,850 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of ALXO’s outstanding common shares.
ALX Oncology Holdings SVP Shelly Wong reported an open-market sale of 1,404 shares of Common Stock at a weighted average price of $2.04 per share. According to the filing, the shares were sold to satisfy her tax obligations related to vesting of restricted stock units.
After this transaction, she directly holds 88,401 shares, which includes 3,000 shares acquired under the company’s employee stock purchase plan on June 30, 2026.
ALX Oncology Holdings Inc. reported a planned leadership transition at the board level. Corey Goodman, Ph.D., co-founder and long-time Chairman, resigned from the board and all its committees effective June 29, 2026, citing personal reasons and no disagreements with the company.
The board appointed existing independent director Scott Garland as Chairman effective the same date and named Michael Listgarten as General Counsel. Committee memberships were updated, with Rekha Hemrajani chairing Audit, Chris Takimoto chairing Compensation, and Daniel J. Curran chairing Corporate Governance and Nominating, reflecting a refreshed governance structure.